 PHILADELPHIA, Nov. 23, 2020 GLOBE NEWSWIRE -- Cabaletta Bio, Inc. Nasdaq: CABA, a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in December: 